Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,
Study shows diabetes drugs' potential beyond weight loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
New study on weight loss drugs
ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.
Taking This Weight-Loss Medication Could Slash Dementia Risk, New Research Suggests
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what to know, per a neurologist.
Outsourcing-pharma20h
Novo Nordisk reports positive results for high-dose Wegovy formulation
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Healio19h
STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...
pharmaphorum2d
High-dose semaglutide ramps up weight loss, says Novo
with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
White House says popular weight-loss drug Ozempic subject to Medicare talks
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...